Skip to main content
Markets
/
ALIVUS · NSE
Market closedNSE | BSE
Loading live market indices
AL
NSE · Equity shares · Biotechnology & Drugs

Alivus Life Sciences ALIVUS

NSE:INR 1,325.2Recorded price
BSE:INR 1,315Recorded price
Not available · Not available
Advanced chart
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceStale · last-known data
Company fundamentalsStale · last-known data
Research sections8 of 9 availableMissing source values remain unavailable, never zero-filled.
Snapshot

Price and key statistics

Reported and computed values remain separate; missing values are not converted to zero.

Previous closeData unavailable
Day rangeINR 1,315 — INR 1,376
52-week rangeINR 830 — INR 1,356.2
VolumeNot available
Market cap16,125.7
P/E23.54
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)2,551.83
Net Income (INR Cr)564.48
Rev Growth (5 Year %)6.24
EPS Growth (5 Year %)9.85
P/E Ratio23.54
EPS47.47

Research path: Interpret Alivus Life Sciences's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.

AI and Advanced

AI analysis and Advanced tools for ALIVUS

Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.

AI analysisReview the complete evidence-led AI research workflow.Generate reportCreate a versioned report with entitlement and credit checks.Open AI ChatContinue a grounded conversation with the instrument in context.Advanced modulesOpen role- and entitlement-controlled portfolio and trading tools.
Validated OHLC

Interactive price chart

Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.

Open full workspace
Interactive price chartInteractive chart loads when this section is visible.
Auditable calculations

Daily technical summary

Calculated from validated daily candles. Descriptive research only.

Calculating technicals…
Intelligence: activity, structure and reported deals

Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.

Company derivatives · NSE

ALIVUS futures & options

Expiry structure, futures, option chains and contract research.

Snapshot · timestamp unavailable
No observations

No matching contracts have verified observations for this filter.

DIRECTION · ACTIVITY · DISCLOSURES

ALIVUS Intelligence

Stored price, volume, causal structure and reported deals for this stock.

Market map
Checking research access…

Volume and pressure are activity estimates, not net money inflow. Futures and options retain their separate observations above.

Company reporting

Financial statements

IND AS · INR crore

Metric202620252024
Total Liabilities Shareholders' Equity3,982.93,411.452,850.41
Cash Equivalents1.9825.02269.6
Other Liabilities Total36.1518.5415.77
Accrued Expenses29.9134.2828.43
Common Stock Total24.5524.5124.51
Other Current Assets Total69.810.30.7
Total Assets3,982.93,411.452,850.41
Current Portof LT Debt/Capital Leases7.985.652.39
Total Equity3,332.132,817.372,332.32
Long Term Investments6.790.080.08
Retained Earnings(Accumulated Deficit)3,307.591,787.151,302.86
Total Common Shares Outstanding12.2712.2512.25
Tangible Book Valueper Share Common Eq269.05228.31189.14
Total Liabilities650.77594.08518.09
Total Debt56.7756.6117.15
Short Term Investments812.67477.61Not available
Cashand Short Term Investments814.65548.68301.41
Total Receivables Net1,072.961,101.72931.95
Deferred Income Tax57.7954.4348.79
Accounts Receivable-Trade Net1,072.96969.74765.43
Property/Plant/Equipment Total-Net1,291.381,036.92896.2
Total Current Liabilities508.04470.16438.77
Total Inventory691.93682.2681.13
Accounts Payable372.37390.46368.66
Other Currentliabilities Total97.7839.7739.3
Total Long Term Debt48.7950.9614.76
Intangibles Net29.9319.9414.85
Other Long Term Assets Total5.446.3711.03
Note Receivable-Long Term012.9912.26
Total Current Assets2,649.362,335.161,916
Capital Lease Obligations48.7950.9614.76
Accumulated Depreciation TotalNot available-253.73-199.36
Prepaid ExpensesNot available2.260.81
Additional Paid-In CapitalNot available1,005.721,004.96
CashNot available46.0431.82
Property/Plant/Equipment Total-GrossNot available1,196.4994.37
Notes Payable/Short Term DebtNot available00
Fundamentals

Valuation and ratios

Valuation

PEG Ratio4.24

Price to Sale Ratio6.32

Margins

Operating Margin 12m28.26

Operating Margin 5y Avg27.13

Net Profit Margin 12m23.28

Net Profit Margin 5y20.92

Yield

Dividend Yield %0.38

Risk and consensus

Source-qualified signals

Risk metrics

Overall RiskBalanced risk

Board Risk30.08

Analyst consensus

ConsensusStrong Buy

Consensus score1.50

Analyst opinions4

Strong Sell count0

Sell count0

Hold count0

Buy count2

Strong Buy count2

Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.
Industry context

Peer comparison

Only peers present in the company profile payload are displayed.

CompanyPriceMarket capP/EResearch
Sun Pharmaceutical IndustriesINR 1,9444.66 L38.4—
Divi's LaboratoriesINR 8,291.552.20 L73.32—
Torrent PharmaceuticalsINR 4,9651.89 L72.73—
CiplaINR 1,4751.19 L27.57—
Zydus LifesciencesINR 1,106.251.10 L21.19—
Shareholding

Ownership

Promoter
74.87%
FII
5.54%
MF
5.65%
Other
13.94%
Corporate actions

Events

  1. board MeetingsQuarterly Results
  2. dividendRs.5.0000 per share(250%)Final Dividend
  3. board MeetingsAudited Results & Final Dividend
  4. board MeetingsQuarterly Results
  5. board MeetingsQuarterly Results
  6. annual General MeetingAGM
  7. dividendRs.5.0000 per share(250%)Final Dividend
  8. board MeetingsQuarterly Results
  9. board MeetingsAudited Results & Final Dividend
  10. board MeetingsQuarterly Results
  11. annual General MeetingPOM
  12. board MeetingsQuarterly Results
  13. annual General MeetingAGM
  14. board MeetingsQuarterly Results
  15. board MeetingsAudited Results
  16. board MeetingsQuarterly Results
  17. board MeetingsQuarterly Results
  18. dividendRs.22.5000 per share(1125%)Interim Dividend
  19. board MeetingsInterim Dividend
  20. annual General MeetingA.G.M.
Rusaka Markets Community

Discussion and sentiment for Alivus Life Sciences

Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.

Rusaka Markets Community

Community discussion loads as you approach this section.

Company profile

Business information

What the company does

Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). It also develops APIs in the therapeutic areas such as antifungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. It has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh.

Company facts

Industry
Biotechnology & Drugs
Sector
Biotechnology & Drugs
NSE Code
ALIVUS
BSE Code
543322
Questions

Stock FAQ

What is the symbol and ISIN of Alivus Life Sciences?

Alivus Life Sciences has the symbol ALIVUS and ISIN - INE03Q201024.

What is the latest recorded price of Alivus Life Sciences?

The latest available recorded price of Alivus Life Sciences is INR 1,325.20 as of 2026-08-06T20:56:34.066Z. This is a source-stamped snapshot, not a live quote.

What are the year high and year low of Alivus Life Sciences?

Year high: INR 1,356.20. Year low: INR 830.00.

What is the market capitalization of Alivus Life Sciences?

Market capitalization: INR 16,125.70 crore.

What is the P/E ratio of Alivus Life Sciences?

P/E ratio: 23.54.

What is the dividend yield of Alivus Life Sciences?

Dividend yield: 0.38%.

How is the financial performance of Alivus Life Sciences based on revenue, net income, and EPS?

Revenue: INR 2,551.83 crore. Net income: INR 564.48 crore. EPS: INR 50.61.

What are the price-to-book and price-to-sales ratios of Alivus Life Sciences?

Price-to-book ratio is unavailable in the current source. Price-to-sales ratio: 6.32.

Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.